KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Co-Diagnostics (CODX) EBT (2017 - 2025)

Historic EBT for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to -$7.1 million.

  • Co-Diagnostics' EBT rose 2709.09% to -$7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$33.3 million, marking a year-over-year increase of 1084.1%. This contributed to the annual value of -$37.6 million for FY2024, which is 138.78% up from last year.
  • According to the latest figures from Q3 2025, Co-Diagnostics' EBT is -$7.1 million, which was up 2709.09% from -$7.7 million recorded in Q2 2025.
  • In the past 5 years, Co-Diagnostics' EBT ranged from a high of $13.6 million in Q3 2021 and a low of -$25.0 million during Q4 2022
  • Moreover, its 5-year median value for EBT was -$7.6 million (2024), whereas its average is -$3.7 million.
  • In the last 5 years, Co-Diagnostics' EBT soared by 102796.47% in 2021 and then crashed by 34447.09% in 2022.
  • Co-Diagnostics' EBT (Quarter) stood at $10.2 million in 2021, then tumbled by 344.47% to -$25.0 million in 2022, then surged by 56.71% to -$10.8 million in 2023, then fell by 1.82% to -$11.0 million in 2024, then surged by 36.11% to -$7.1 million in 2025.
  • Its EBT stands at -$7.1 million for Q3 2025, versus -$7.7 million for Q2 2025 and -$7.5 million for Q1 2025.